Table II.
The Aryl Hydrocarbon Receptor in models of disease.
| Disease | Summary of Selected Reference | Selected Reference | Other References |
|---|---|---|---|
| Cancer | Kynurenine is an endogenous AHR ligand that suppresses anti-tumor immune responses. | (35) | (64, 71–76) |
| Infection & Immunity | TCDD treatment reduces the severity of HSV-mediated inflammatory lesions in the cornea. | (39) | (77–82) |
| Allergy & Asthma | Food allergy is reduced by AHR activation in a murine peanut allergy model. Allergic lung inflammation is inhibited by pharmacological AHR activation. |
(83) (41) |
(84–89) |
| Gastrointestinal | TCDD treatment reduced colonic inflammation in a murine model of Crohn’s disease. | (90) | (42, 44, 91) |
| Autoimmunity | AHR expression is required in a murine model of rheumatoid arthritis. Treatment with FICZ accelerates while TCDD delays clinical onset of EAE |
(40) (17, 18) |
(92–94) |
| Transplantation | Allograft-acceptance promoted by pharmacologic-activation of the AHR. Treatment with FICZ accelerates while TCDD delays rejection of allogeneic skin grafts. |
(56) (57) |